CoChat

Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring

Open access
van Oostveen, Wieke M., de Lange, Elizabeth C. M. · 2021 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 228 of the 232 references it cites were found in a registry or an index.

Abstract

Background. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting many individuals worldwide with no effective treatment to date. AD is characterized by the formation of senile plaques and neurofibrillary tangles, followed by neurodegeneration, which leads to cognitive decline and eventually death. Introduction. In AD, pathological changes occur many years before disease onset. Since disease-modifying therapies may be the most beneficial in the early stages of AD, biomarkers for the early diagnosis and longitudinal monitoring of disease progression are essential. Multiple imaging techniques with associated biomarkers are used to identify and monitor AD. Aim. In this review, we discuss the contemporary early diagnosis and longitudinal monitoring of AD with imaging techniques regarding their diagnostic utility, benefits and limitations. Additionally, novel techniques, applications and biomarkers for AD research are assessed. Findings. Reduced hippocampal volume is a biomarker for neurodegeneration, but atrophy is not an AD-specific measure. Hypometabolism in temporoparietal regions is seen as a biomarker for AD. However, glucose uptake reflects astrocyte function rather than neuronal function. Amyloid-β (Aβ) is the earliest hallmark of AD and can be measured with positron emission tomography (PET), but Aβ accumulation stagnates as disease progresses. Therefore, Aβ may not be a suitable biomarker for monitoring disease progression. The measurement of tau accumulation with PET radiotracers exhibited promising results in both early diagnosis and longitudinal monitoring, but large-scale validation of these radiotracers is required. The implementation of new processing techniques, applications of other imaging techniques and novel biomarkers can contribute to understanding AD and finding a cure. Conclusions. Several biomarkers are proposed for the early diagnosis and longitudinal monitoring of AD with imaging techniques, but all these biomarkers have their limitations regarding specificity, reliability and sensitivity. Future perspectives. Future research should focus on expanding the employment of imaging techniques and identifying novel biomarkers that reflect AD pathology in the earliest stages.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms22042110

Cites

228 of 228 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The Alzheimer’s disease continuum with corresponding pathological changes, biomarkers and clinical diagnosis. Figure adapted from Yoshiyama et al. [21].
Figure 1 The Alzheimer’s disease continuum with corresponding pathological changes, biomarkers and clinical diagnosis. Figure adapted from Yoshiyama et al. [21].CC BY · PubMed Central
Figure 6 Tau spreading pattern in each Braak stage. Spreading pattern of tau throughout the brain from Braak stage I-II to stage III-IV (limbic regions) and stage V-VI (isocortical areas). Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).
Figure 6 Tau spreading pattern in each Braak stage. Spreading pattern of tau throughout the brain from Braak stage I-II to stage III-IV (limbic regions) and stage V-VI (isocortical areas). Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).CC BY · PubMed Central
Figure 2 Regions affected by Alzheimer’s disease. Figure created with www.BioRender.com (accessed on 12 February 2021).
Figure 2 Regions affected by Alzheimer’s disease. Figure created with www.BioRender.com (accessed on 12 February 2021).CC BY · PubMed Central
Figure 3 Neuroimages of the healthy versus the Alzheimer’s disease (AD) brain. Neuroimaging with (a) structural MRI, (b) FDG-PET, (c) amyloid-PET with PiB and (d) tau PET with 18F-AV1451 in both healthy and AD brains. Figure created with www.BioRender.com (accessed on 14 February 2021).
Figure 3 Neuroimages of the healthy versus the Alzheimer’s disease (AD) brain. Neuroimaging with (a) structural MRI, (b) FDG-PET, (c) amyloid-PET with PiB and (d) tau PET with 18F-AV1451 in both healthy and AD brains. Figure created with www.BioRender.com (accessed on 14 February 2021).CC BY · PubMed Central
Figure 4 Accumulation of amyloid-β in AD. Figure adapted from Patterson et al. [89] and created with www.BioRender.com (accessed on 16 November 2020).
Figure 4 Accumulation of amyloid-β in AD. Figure adapted from Patterson et al. [89] and created with www.BioRender.com (accessed on 16 November 2020).CC BY · PubMed Central
Figure 5 Tau protein aggregation leads to formation of neurofibrillary tangles in AD. (a) Role of tau protein in healthy brain; (b) role of tau protein in Alzheimer’s disease brain. NFT: neurofibrillary tangles; PHF: paired helical filaments. Figure adapted from “Pathology of Alzheimer’s Disease”, by BioRender.com (2020). Retrieved from https://app.biorender.com/biorender-templates (accessed on 16 November 2020).
Figure 5 Tau protein aggregation leads to formation of neurofibrillary tangles in AD. (a) Role of tau protein in healthy brain; (b) role of tau protein in Alzheimer’s disease brain. NFT: neurofibrillary tangles; PHF: paired helical filaments. Figure adapted from “Pathology of Alzheimer’s Disease”, by BioRender.com (2020). Retrieved from https://app.biorender.com/biorender-templates (accessed on 16 November 2020).CC BY · PubMed Central
Figure 7 AD leads to hippocampal atrophy and ventricle enlargement. Healthy brain (left) versus AD brain (right). AD leads to decreased hippocampal volume, shrinkage of cerebral cortex and ventricle enlargement. MTA: medial temporal lobe atrophy; MTA = 0: no atrophy in medial temporal lobe; MTA = 4: severe volume loss of hippocampus. Figure created with www.BioRender.com (accessed on 14 February 2021).
Figure 7 AD leads to hippocampal atrophy and ventricle enlargement. Healthy brain (left) versus AD brain (right). AD leads to decreased hippocampal volume, shrinkage of cerebral cortex and ventricle enlargement. MTA: medial temporal lobe atrophy; MTA = 0: no atrophy in medial temporal lobe; MTA = 4: severe volume loss of hippocampus. Figure created with www.BioRender.com (accessed on 14 February 2021).CC BY · PubMed Central
Figure 8 Spreading pattern of amyloid-β accumulation throughout the brain. Amyloid-β accumulation starts in frontal areas and spreads to other regions as disease progresses, leading to a plateau in amyloid-β as disease progresses. Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).
Figure 8 Spreading pattern of amyloid-β accumulation throughout the brain. Amyloid-β accumulation starts in frontal areas and spreads to other regions as disease progresses, leading to a plateau in amyloid-β as disease progresses. Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–228 of 228

Cited by

See all 351

Metadata

Authors
van Oostveen, W. M., & de Lange, E. C. M.
Affiliations
  • Faculty of Science, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
  • Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre of Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-02-20
Volume
22
Issue
4
Pages
2110
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3131910442
Cited by
297
References
232
Citations by year
2026: 47 · 2025: 84 · 2024: 75 · 2023: 55 · 2022: 24 · 2021: 11
FWCI
7.53
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
Alzheimer's disease, neuroimaging biomarkers, early diagnosis, longitudinal disease monitoring, amyloid PET, hippocampal atrophy, hypometabolism, glucose uptake, neurodegeneration, disease-modifying therapy
MeSH terms
Alzheimer Disease, Amyloid, Humans, Longitudinal Studies, Biomarkers, Early Diagnosis, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.